• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4595849)   Today's Articles (57)   Subscriber (49336)
Number Citation Analysis
51
Yang J., Wu Y, Hirsh V, O’Byrne K, Yamamoto N, Popat S, Tamiya A, Kaen D, Märten A, Schuler M. P06 Competing CNS or Systemic Progression Analysis for EGFR Mutation-Positive NSCLC Patients on Afatinib in LUX-Lung 3, 6, and 7. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.07.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
52
Markus M, Streibelt M, Schuler M, Gerlich C, Bethge M. Wirksamkeit medizinisch-beruflich orientierter Rehabilitation in der orthopädischen Versorgungsrealität. DAS GESUNDHEITSWESEN 2018. [DOI: 10.1055/s-0038-1667737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
53
Heß V, Schuler M, Meng K, Schulte T, Bengel J, Faller H. Psychosoziale Bedürfnisse und Belastungen bei onkologischen Rehabilitanden: Warum werden sie im Aufnahmegespräch nicht geäußert bzw. erkannt? Psychother Psychosom Med Psychol 2018. [DOI: 10.1055/s-0038-1667991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
54
Bethge M, Markus M, Streibelt M, Gerlich C, Schuler M. From evidence to practice: Improving work participation outcomes by work-related medical rehabilitation in patients with chronic musculoskeletal diseases. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.945] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
55
Alma HJ, de Jong C, Jelusic D, Wittmann M, Schuler M, Kollen BJ, Sanderman R, Schultz K, Kocks JWH, Van der Molen T. Assessing health status over time: impact of recall period and anchor question on the minimal clinically important difference of copd health status tools. Health Qual Life Outcomes 2018;16:130. [PMID: 29940980 PMCID: PMC6019834 DOI: 10.1186/s12955-018-0950-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2017] [Accepted: 05/30/2018] [Indexed: 12/17/2022]  Open
56
Guberina M, Eberhardt W, Stuschke M, Gauler T, Cheufou D, Schuler M, Stamatis G, Pöttgen C. OC-0493: Pretreatment metabolic volume in PET: Prognostic in lung cancer? German ESPATUE randomised phase3trial. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30803-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
57
Szentes B, Schwarzkopf L, Lehbert N, Wittmann M, Wagner R, Nowak D, Faller H, Schuler M, Schultz K. Is EQ-5D suited to assess quality of life aspects in pulmonary rehabilitation in bronchial asthma. Pneumologie 2018. [DOI: 10.1055/s-0037-1619413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
58
Schultz K, Wittmann M, Wagner R, Schwarzkopf L, Nowak D, Faller H, Schuler M. Stimmt der Asthmakontrolltest (ACT) mit den überarbeiteten GINA-Kriterien der Asthmasymptomkontrolle (ASC) überein? Pneumologie 2018. [DOI: 10.1055/s-0037-1619163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
59
Ahnert J, Schuler M, Legner R, Schmale R, Berger H, Vogel H. Anträge auf psychosomatische Rehabilitation – Häufigkeit, Qualität und Befürwortungsrate. DAS GESUNDHEITSWESEN 2018;80:232-239. [DOI: 10.1055/s-0042-106968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
60
Schultz K, Wittmann M, Wagner R, Schwarzkopf L, Nowak D, Schuler M. Tabakentwöhnung (TEW) in der pneumologischen Rehabilitation (PR) von Asthmatikern. Pneumologie 2018. [DOI: 10.1055/s-0037-1619273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
61
Mühlig S, Schultz K, Loth F, Schuler M, Wittmann M. Interdependenz von Rauchen und psychischer Komorbidität bei COPD-Patienten: Empirische Daten aus der pneumologischen Rehabilitation. Pneumologie 2018. [DOI: 10.1055/s-0037-1619274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
62
Cutolo G, Reise F, Schuler M, Nehmé R, Despras G, Brekalo J, Morin P, Renard PY, Lindhorst TK, Tatibouët A. Bifunctional mannoside–glucosinolate glycoconjugates as enzymatically triggered isothiocyanates and FimH ligands. Org Biomol Chem 2018;16:4900-4913. [DOI: 10.1039/c8ob01128a] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
63
Hirsh V, Tan E, Wu Y, Sequist L, Zhou C, Schuler M, Geater S, Mok T, Hu C, Yamamoto N, Feng J, O’Byrne K, Lu S, Huang Y, Sebastian M, Okamoto I, Dickgreber N, Shah R, Palmer M, Märten A, Massey D, Samuelsen C, Yang J. P3.01-075 Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm+ NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
64
Park K, Tan E, O’Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang J, Schuler M, Yamamoto N, Sequist L, Wu Y, Zhou C, Ehrnrooth E, Märten A, Tang W, Paz-Ares L. P3.01-039 Sequential Afatinib-Osimertinib Therapy in EGFR Mutation-Positive (EGFRm+) NSCLC: Analysis of Time on Treatment and OS. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1480] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
65
Schuler M, Yang J, Sequist L, Wu Y, Zhou C, Geater S, Mok T, Tan E, Hu C, Yamamoto N, Feng J, O’Byrne K, Lu S, Hirsh V, Huang Y, Ellis S, Samuelsen C, Märten A, Fan J, Park K, Paz-Ares L. P3.01-026 Analysis of Long-Term Response to First-Line Afatinib in the LUX-Lung 3, 6 and 7 Trials in Advanced EGFRm+ NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
66
Sequist L, Wu Y, Schuler M, Kato T, Yang J, Tanaka H, Hida T, Lu S, Park K, Paz-Ares L, Laurie S, Bennouna J, Moro Sibilot D, Märten A, Tang W, Ehrnrooth E, Yamamoto N, Nakagawa K. PS02.20 Subsequent Therapies Post-Afatinib Among Patients with EGFR Mutation-Positive (EGFRm+) NSCLC in LUX-Lung 3, 6 and 7. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.058] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
67
Shaw A, Kim D, Solomon B, Felip E, Riely G, Schuler M, Tan D, Chow L, Camidge D, Urban P, Ortmann C, Malet I, Mehra R. P1.01-012 Ceritinib in Anaplastic Lymphoma Kinase (ALK)+ NSCLC Patients Pretreated With Only Crizotinib: ASCEND-1 Subgroup Analysis. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
68
Schuler M, Nogova L, Heidenreich A, Tai D, Cassier P, Richly H, Cho B, Sayehli C, Navarro A, Bender S, Ocker M, Nogai H, Wagner A, Ince S, Ellinghaus P, Joerger M. Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx371.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
69
Al-Batran SE, Pauligk C, Homann N, Schmalenberg H, Kopp HG, Haag G, Luley K, Folprecht G, Probst S, Thuss-Patience P, Trojan J, Koenigsmann M, Lindig U, Pohl M, Kasper S, Möhler M, Goetze T, Schuler M, Jaeger E, Hofheinz R. Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.019] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
70
Joerger M, Soo R, Cho B, Navarro A, Sayehli C, Richly H, Tai D, Kim DW, Wolf J, Cassier P, Bender S, Ellinghaus P, Ince S, Rajagopalan P, Ocker M, Schuler M. A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx367.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
71
Hamacher R, Kämpfe D, Ahrens M, Reuter-Jessen K, Schuler M, Schildhaus HU, Bauer S. PD-L1 inhibition – a new therapeutic opportunity in cutaneous angiosarcoma? Ann Oncol 2017. [DOI: 10.1093/annonc/mdx387.032] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
72
Kasper B, Reichardt P, Schuler M, Hohenberger P. Geriatric assessment of elderly chemotherapy-naïve patients treated with trabectedin for advanced soft tissue sarcomas (STS): The E-TRAB study of the German Interdisciplinary Sarcoma Group (GISG-13). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx387.050] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
73
Sequist L, Wu YL, Schuler M, Kato T, Yang JH, Tanaka H, Hida T, Lu S, Park K, Laurie S, Bennouna J, Moro Sibilot D, Märten A, Peil B, Ehrnrooth E, Yamamoto N, Nakagawa K. Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.051] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
74
Sahin U, Schuler M, Bauer S, Krilova A, Utsch M, Huber C, Türeci Ö. First-in-human study of IMAB362, an anti-claudin 18.2 monoclonal antibody, in patients with advanced gastroesophageal cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
75
Sauer R, Kiewe P, Desole M, Schuler M, Theissig F, Roth A, Mairinger T. Lymphozytäre Myokarditis unter Nivolumabtherapie bei metastasiertem klarzelligen Nierenzellkarzinom. DER PATHOLOGE 2017;38:535-539. [DOI: 10.1007/s00292-017-0349-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
PrevPage 3 of 13 123451213Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA